Bioinformatics and in-silico findings reveal medical features and pharmacological targets of biochanin A against colorectal cancer and COVID-19.
Bioengineered
; 12(2): 12461-12469, 2021 12.
Article
in English
| MEDLINE | ID: covidwho-1585255
ABSTRACT
Severe mortality due to the COVID-19 pandemic resulted from the lack of effective treatment. Although COVID-19 vaccines are available, their side effects have become a challenge for clinical use in patients with chronic diseases, especially cancer patients. In the current report, we applied network pharmacology and systematic bioinformatics to explore the use of biochanin A in patients with colorectal cancer (CRC) and COVID-19 infection. Using the network pharmacology approach, we identified two clusters of genes involved in immune response (IL1A, IL2, and IL6R) and cell proliferation (CCND1, PPARG, and EGFR) mediated by biochanin A in CRC/COVID-19 condition. The functional analysis of these two gene clusters further illustrated the effects of biochanin A on interleukin-6 production and cytokine-cytokine receptor interaction in CRC/COVID-19 pathology. In addition, pathway analysis demonstrated the control of PI3K-Akt and JAK-STAT signaling pathways by biochanin A in the treatment of CRC/COVID-19. The findings of this study provide a therapeutic option for combination therapy against COVID-19 infection in CRC patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Colorectal Neoplasms
/
Gene Expression Regulation, Neoplastic
/
Anticarcinogenic Agents
/
Genistein
/
Phytoestrogens
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
/
Systematic review/Meta Analysis
Topics:
Vaccines
Language:
English
Journal:
Bioengineered
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS